

Albiruni R A Razak

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1272618/albiruni-r-a-razak-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78
papers

1,578
citations

21
h-index

38
g-index

83
ext. papers

2,001
ext. citations

4.1
avg. IF

4.11
L-index

#	Paper	IF	Citations
78	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101829	2.2	1
77	A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS). <i>European Journal of Cancer</i> , 2021 , 144, 360-367	7.5	2
76	Selinexor, a First in Class, Nuclear Export Inhibitor for the Treatment of Advanced Malignant Peripheral Nerve Sheath Tumor. <i>Oncologist</i> , 2021 , 26, e710-e714	5.7	3
75	291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors 2020 , 8, A318-A318		2
74	Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. <i>F1000Research</i> , 2020 , 9, 337	3.6	2
73	Characterization and outcomes of patients enrolled to multiple phase I cancer trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 469-472	3.5	
72	Curability of patients with lymph node metastases from extremity soft-tissue sarcoma. <i>Cancer</i> , 2020 , 126, 5098-5108	6.4	8
71	Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors 2020 , 8,		25
70	Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.. <i>Nature Cancer</i> , 2020 , 1, 873-881	15.4	89
69	An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors 2020 , 8,		12
68	Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. <i>Cancer Cell</i> , 2019 , 35, 738-751.e9	24.3	93
67	An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE) 2019 , 7, 72		16
66	Hyperprogressive disease in advanced triple-negative breast cancer (aTNBC) treated with immunotherapy (IO).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1086-1086	2.2	1
65	Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single-agent pembrolizumab (P).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2542-2542	2.2	3
64	Phase 1b study of selinexor, a first-in-class selective inhibitor of nuclear export (SINE) compound, in combination with doxorubicin in patients (pts) with locally advanced or metastatic soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3123-3123	2.2	1
63	ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).. <i>Journal of Clinical Oncology</i> , 2019 , 37, LBA3-LBA3	2.2	38
62	Is PAX3-FOXO1 associated with worse outcome in adults with rhabdomyosarcoma (RMS)?.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e22525-e22525	2.2	

61	Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. <i>Cancer</i> , 2019 , 125, 1341-1349	6.4	78
60	Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era. <i>Oncologist</i> , 2019 , 24, e518-e525	5.7	
59	Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library. <i>Oncologist</i> , 2019 , 24, e146-e148	5.7	14
58	Ending 40 years of silence: Rationale for a new staging system for soft tissue sarcoma of the head and neck. <i>Clinical and Translational Radiation Oncology</i> , 2019 , 15, 13-19	4.6	3
57	Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma. <i>International Journal of Cancer</i> , 2018 , 142, 57-65	7.5	20
56	Abstract CT009: Results of a dose- and regimen-finding Phase Ib study of HDM201 in combination with ribociclib in patients with locally advanced or metastatic liposarcoma 2018 ,		5
55	Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11511-11511	2.2	3
54	Phase 2 results of selinexor in advanced de-differentiated (DDLs) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11512-11512	2.2	13
53	Phase 1b study of selinexor, a first in class selective inhibitor of nuclear export (SINE) compound, in combination with doxorubicin in patients (pts) with locally advanced or metastatic soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11562-11562	2.2	1
52	Hyperprogressive disease (HPD) in early-phase immunotherapy (IO) trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3063-3063	2.2	4
51	Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8517-8517	2.2	17
50	Tumor necrosis and clinical outcomes following neoadjuvant therapy in soft tissue sarcoma: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018 , 69, 1-10	14.4	25
49	Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck. <i>Cancer Treatment Reviews</i> , 2017 , 54, 43-57	14.4	11
48	Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs. <i>Clinical Cancer Research</i> , 2017 , 23, 4020-4026	12.9	9
47	Determinants of the recommended phase 2 dose of molecular targeted agents. <i>Cancer</i> , 2017 , 123, 1409-1415	11.5	4
46	Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 1552-1563	12.9	49
45	Immunoprofiling in alveolar soft part sarcoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11059-11059	2.2	4
44	Pharmacokinetic-driven phase I study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients (pts) with gastrointestinal stromal tumor (GIST) and other solid tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2515-2515	2.2	5

43	Phase I study of oncolytic virus (OV) MG1 maraba/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e14637-e14637	2.2	6
42	Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6514-6514	2.2	
41	Validation of the Princess Margaret immune oncology prognostic index (PM-IPI) for patients (pts) treated in immune oncology (IO) early phase trials.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3070-3070	2.2	
40	Phase I study of CFI-402257, an oral TTK inhibitor, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS2619-TPS2619	2.2	
39	A technical feasibility report on correlative studies from the investigator-initiated phase II study of pembrolizumab (Pembro) immunological response evaluation (INSPIRE).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11607-11607	2.2	
38	Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3166-74	2.2	107
37	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , 2016 , 8, 109	14.4	149
36	Evolution of Randomized Trials in Advanced/Metastatic Soft Tissue Sarcoma: End Point Selection, Surrogacy, and Quality of Reporting. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1469-75	2.2	27
35	The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, multicenter, randomized, double blind study of selinexor versus placebo in patients with advanced, unresectable, dedifferentiated liposarcoma (DDLs).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS11072-TPS11072	2.2	2
34	Association of isocitrate dehydrogenase-1 (IDH-1) mutations with elevated oncometabolite 2-hydroxyglutarate (2HG) in advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 627-627	2.2	4
33	IDH-1/2 mutations and associated oncometabolite 2-hydroxyglutarate (2-HG) in solid tumors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e23210-e23210	2.2	
32	Reply to L.A. Renfro et al. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3950	2.2	
31	A multicenter phase 1 study of βsecretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. <i>Investigational New Drugs</i> , 2015 , 33, 169-76	4.3	30
30	A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015 , 33, 1100-7	4.3	85
29	Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2590-2590	2.2	2
28	Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4516-4516	2.2	40
27	Differential impact of cisplatin dose intensity on human papillomavirus (HPV)-related (+) and HPV-unrelated (−) locally advanced head and neck squamous cell carcinoma (LAHNSCC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6020-6020	2.2	6
26	Developing a Cancer genomics Digital Educational Tool to assess the knowledge and expectations of patients with advanced solid tumors (CADET).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6524-6524	2.2	

25	A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). <i>Investigational New Drugs</i> , 2014 , 32, 243-9	4.3	63
24	A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. <i>Investigational New Drugs</i> , 2014 , 32, 1269-77	4.3	38
23	Phase II study of oral ENMD-2076 administered to patients (pts) with advanced soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10528-10528	2.2	2
22	A phase 1b food effect study of the first-in-class, oral, selective inhibitor of nuclear export (SINE) selinexor (KPT-330) in patients (pts) with advanced sarcomas.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10587-10587	2.2	1
21	A phase 1b study of combined angiogenesis blockade with nesvacumab, a selective monoclonal antibody (MAb) to angiopoietin-2 (Ang2) and ziv-aflibercept in patients with advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2522-2522	2.2	3
20	A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2537-2537	2.2	1
19	A systematic review of immune-related adverse event (irAE) reporting in clinical trials of immune checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3057-3057	2.2	1
18	Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4504-4504	2.2	61
17	Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist KPT-330 (Selinexor) in patients (pts) with platinum-resistant/refractory ovarian cancer (OvCa).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5522-5522	2.2	2
16	Preoperative window-of-opportunity (WOO) study of dacomitinib (Dac) in patients (Pts) with resectable oral cavity squamous cell carcinoma (OCC): Generation of a gene expression signature (DGS) as a predictor of Dac activity.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6041-6041	2.2	4
15	Phase Ib/II study of the PI3K inhibitor BYL719 in combination with cetuximab in recurrent/metastatic squamous cell cancer of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6044-6044	2.2	13
14	Safety and antitumor activity of selinexor (KPT-330), a first-in-class, oral XPO1 selective inhibitor of nuclear export: A phase I study expanded with colon cancer cohort.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 482-482	2.2	3
13	Phase 1 first-in-human (FIH) study of nesvacumab (REGN910) a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb): Results from hepatocellular carcinoma (HCC) cohort.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2540-2540	2.2	
12	Choice of starting dose for biopharmaceuticals in first-in-human phase I cancer clinical trials.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2596-2596	2.2	
11	Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls. <i>Clinical and Translational Oncology</i> , 2012 , 14, 15-20	3.6	21
10	Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents. <i>PLoS ONE</i> , 2012 , 7, e51039	3.7	29
9	Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature. <i>European Journal of Cancer</i> , 2011 , 47, 1468-75	7.5	44
8	Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland. <i>British Journal of Ophthalmology</i> , 2011 , 95, 1483-9	5.5	25

7	Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease. <i>The Cochrane Library</i> , 2011 , CD007584	5.2	6
6	Extrasosseous pericardial Ewing@ sarcoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, e48-50	2.2	7
5	Molecular targeted therapies in all histologies of head and neck cancers: an update. <i>Current Opinion in Oncology</i> , 2010 , 22, 212-20	4.2	20
4	Nasopharyngeal carcinoma: the next challenges. <i>European Journal of Cancer</i> , 2010 , 46, 1967-78	7.5	181
3	Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?. <i>Lung Cancer</i> , 2009 , 64, 207-10	5.9	6
2	Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option. <i>Lung Cancer</i> , 2008 , 60, 294-7	5.9	21
1	Medulloblastoma in two successive pregnancies. <i>Journal of Neuro-Oncology</i> , 2005 , 73, 89-90	4.8	7